Core Viewpoint - The company has selected ASC35, a potential best-in-class monthly subcutaneous injection GLP-1R/GIPR dual agonist peptide, as a clinical development candidate for obesity treatment, with plans to submit an IND application to the FDA in Q2 2026 [1] Group 1: Product Development - ASC35 is expected to demonstrate best-in-class efficacy and a monthly dosing frequency, which may lead to superior weight loss results and a more patient-friendly titration scheme [1] - The initiation of clinical development for ASC35 highlights the company's commitment to innovation and complements its small molecule drug pipeline targeting obesity and other metabolic diseases [1] Group 2: Strategic Vision - The founder and CEO of the company emphasized the strategic importance of ASC35 in enhancing the company's portfolio and addressing unmet needs in obesity treatment [1]

Core Viewpoint - The company, Gilead Sciences, has selected ASC35 as a clinical development candidate, which is expected to be a best-in-class monthly subcutaneous injection GLP-1R/GIPR dual agonist for treating obesity and related metabolic diseases [1] Group 1 - Gilead plans to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 for ASC35 [1] - ASC35 is being developed as both a monotherapy and in combination therapy for treating cardiovascular metabolic diseases, including obesity, diabetes, and metabolic dysfunction-associated steatotic liver disease (MASH) [1]